Similar articles

• Growth differentiation factor 5 exerts neuroprotection in an α-synuclein rat model of Parkinson's disease.

  Goulding SR, Concannon RM, Morales-Prieto N, Villalobos-Manriquez F, Clarke G, Collins LM, Lévesque M, Wyatt SL, Sullivan AM, O'Keeffe GW. Goulding SR, et al. Brain. 2021 Mar 3;144(2):e14. doi: 10.1093/brain/awaa367. Brain. 2021. PMID: 33253375 No abstract available.
• BMP5/7 protect dopaminergic neurons in an α-synuclein mouse model of Parkinson's disease.

  Vitic Z, Safory H, Jovanovic VM, Sarusi Y, Stavsky A, Kahn J, Kuzmina A, Toker L, Gitler D, Taube R, Friedel RH, Engelender S, Brodski C. Vitic Z, et al. Brain. 2021 Mar 3;144(2):e15. doi: 10.1093/brain/awaa368. Brain. 2021. PMID: 33253359 Free PMC article. No abstract available.
• Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.

  Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M. Febbraro F, et al. Exp Neurol. 2013 Sep;247:45-58. doi: 10.1016/j.expneurol.2013.03.017. Epub 2013 Mar 24. Exp Neurol. 2013. PMID: 23531432
• Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease.

  Bobela W, Aebischer P, Schneider BL. Bobela W, et al. Biomolecules. 2015 Oct 16;5(4):2675-700. doi: 10.3390/biom5042675. Biomolecules. 2015. PMID: 26501339 Free PMC article. Review.
• Alpha-synuclein-based models of Parkinson's disease.

  Dehay B, Fernagut PO. Dehay B, et al. Rev Neurol (Paris). 2016 Jun-Jul;172(6-7):371-8. doi: 10.1016/j.neurol.2016.04.003. Epub 2016 May 2. Rev Neurol (Paris). 2016. PMID: 27158042 Review.